<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109404</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC19.0030</org_study_id>
    <nct_id>NCT04109404</nct_id>
  </id_info>
  <brief_title>Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin</brief_title>
  <acronym>MAP</acronym>
  <official_title>Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin: Retrospective Study in Patients Followed at the CHRU of Brest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE
      ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and
      treatement of the patients follow up in CHRU of Brest
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective study in CHRU of brest, the investigators selected patient with history of
      méningioma and treated by CYPROTERONE ACETATE, CHLORMADINONE ACETATE and NOMEGESTROL ACETATE
      essentially The investigators excluded patient with risk factor of meningioma added at
      hormonal treatment exposition The investigators discribe the caractéristique of patients:
      age, sex, duration of the treatment, the caractéristique of the meningioma: localization,
      grade, hormonal receptors, treatment by surgery or radiotherapy and changing after
      discontinuation of treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of meningiomas caracteristics</measure>
    <time_frame>12 months</time_frame>
    <description>meningiomas caracteristics in patient treated with CYPROTERONE ACETATE or Progestin description</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prescription status of progestogenic treatment</measure>
    <time_frame>12 months</time_frame>
    <description>indications, duration of treatment, name and type of treatment</description>
  </secondary_outcome>
  <enrollment type="Actual">110</enrollment>
  <condition>Meningioma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        6 men/110, 104 women/110 sex ratio 17.5:1 average duration of follow up: 5.5 years average
        age at diagnosis: 54 +/- 13 years
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  minimum 18 years

          -  medical follow up in CHRU of Brest

          -  treated by CYPROTERONE ACETATE and/or CHLORMADINONE ACETATE NOMEGESTROL ACETATE,
             PROGESTERONE , DYDROGESTERONE PROMEGESTONE , NORETHISTERONE, LEVONORGESTREL ,
             oestroprogestogenic contraception

          -  meningioma after treatement by progestin or CYPROTERONE ACETATE

        Exclusion Criteria:

          -  history ofbreast cancer

          -  history of cerebral radiotherapy

          -  history of neurofibromatosis

          -  meningioma before treatement by progestin or CYPROTERONE ACETATE

          -  minor patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Véronique KERLAN, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Endocrinologie-Diabétologie - CHRU de Brest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Département de Nutrition - CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Acetate-de-chlormadinone-Luteran-R-et-generiques-acetate-de-nomegestrol-Lutenyl-R-et-generiques-risque-de-survenue-de-meningiome-Lettre-aux-professionnels-de-sante</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M, George B, Froelich S. Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir (Wien). 2015 Oct;157(10):1741-6. doi: 10.1007/s00701-015-2532-3. Epub 2015 Aug 12.</citation>
    <PMID>26264069</PMID>
  </reference>
  <reference>
    <citation>S. Froelich, &quot;Does cyproterone acetate promote multiple meningiomas?,&quot; 2009.</citation>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meningioma,</keyword>
  <keyword>progestin,</keyword>
  <keyword>cyproterone acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

